Study shows wearable Parkinson’s monitor, which uses machine learning to detect and assess motor symptoms, is more than 95 per cent accurate when compared to expert evaluation

London, UK, 30 May 2023: The results of a multi-site clinical study analysing the performance of PDMonitor, a pioneering Parkinson’s Disease monitoring device from PD Neurotechnology® that uses wearables and Artificial Intelligence (AI) to track and assess symptoms, have been published in Frontiers in Neurology, a leading peer-reviewed clinical neurology journal.

The study compared PDMonitor® ’s automated assessments of Parkinson’s patients at three European hospitals with physicians’ clinical evaluations and symptom diaries to help determine whether the device provided a reliable and feasible means of informing treatment plans. PDMonitor uses five sensors worn on the patient’s trunk and limbs to gather data about the timing and severity of symptoms, and machine learning algorithms to complete its assessments.

Statistical analysis demonstrated a high level of accuracy in symptom detection and a strong correlation with expert evaluation when assessing their severity. PDMonitor® achieved accuracy and specificity levels of 99 per cent or more when detecting mild to severe dyskinesia, gait impairment, wrist and leg tremor, and at least 96 per cent when detecting ‘Off’ periods when Parkinson’s symptoms re-emerge between medication doses.

A second study, details of which were also published in Frontiers in Neurology, confirmed that PDMonitor® can be used effectively and easily by patients and caregivers, taking just five minutes, on average, to attach the sensors, even for patients at later stages of the disease. Automatic recording and identification of each sensor’s location on the patient’s body were found to further improve the ease of using the device.

These peer-reviewed papers are part of a growing body of evidence highlighting the accuracy and efficacy of PDMonitor®. Preliminary findings from the analysis of data about 267 patients in Greece provide evidence that continuous telemonitoring in clinical practice can lead to the alleviation of Parkinson’s symptoms. The average ‘Off’ time experienced by patients in this study fell for two consecutive quarters following the introduction of PDMonitor®.

In January 2023, PDMonitor® was one of five devices to be conditionally recommended for remote monitoring of Parkinson's disease to inform treatment by NICE, the National Institute for Health and Care Excellence. This decision opened the door to the use of PDMonitor® by NHS patients and their physicians in the UK.

Nikos Moschos, Managing Director of PD Neurotechnology®, comments: “Our monitoring device is a game-changer in the fight against Parkinson’s. Studies confirm that it is effective and easy to use, and we have seen time and again how it facilitates better treatment decisions for patients based on real-world data. By providing accurate and continuous data on symptoms, together with an ecosystem to collect and present effectively, we are always aiming to help improve the management of Parkinson’s and hopefully enhance patients' quality of life.”

Professor K Ray Chaudhuri, Head of Parkinson's Foundation Centre of Excellence at King's College Hospital, who has been piloting PDMonitor® with private patients since March 2022, comments: “Parkinson’s is the world’s second most common neurodegenerative disease and a significant cause of disability at a huge societal cost. Patients’ quality of life and wellness strongly depend on the consistent, prompt monitoring of disease progression and optimal timing and dosing of the prescribed therapy.”

“PDMonitor® is supporting an emerging paradigm shift in Parkinson’s care by moving from traditional short lived face to face consultations to be augmented by home monitoring which has many advantages similar to monitoring in diabetes and cardiac disorders.

"Monitoring patients at home, continuously while they conduct everyday activities, allows treatment decisions to be made more frequently and physicians to respond faster to changing symptoms.

"A major advantage of PDMonitor ® is its ability to provide a self-monitoring platform for patients in addition to monitoring gait and risk of falls , gait and bone health being a major feature in the recently described 'dashboard of vitals' of Parkinson's Disease.

“While you cannot reverse Parkinson’s, one can delay the deterioration of symptoms and possibly decrease the risk of falling. Mobility, falls and related fractures remain a major cause of morbidity and hospitalisation in Parkinson's Disease. Prudent use of PDMonitor® data therefore means accurate assessment with snapshot of home activities so as to provide a dashboard based bespoke personalised care."

About PD Neurotechnology ®:
PD Neurotechnology® is a medical device company transforming healthcare for millions of people worldwide with Parkinson's Disease. Its patented technology enables continuous monitoring of Parkinson's symptoms in the real world, providing physicians with objective data to fine-tune patients' treatment plans and improve symptom management. PD Neurotechnology® is based in London, UK, and its research and development, production, sales and marketing operations are located in Ioannina and Athens, Greece.

For more information please contact:
James Taylor | Roaring Mouse Public Relations
T: (0)1246 938833 | M: +44 (0)7796 138291